{"url_path":"/sec/pmn/8-k/2026-05-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1374339/0001104659-26-064545-index.html","accession_number":"0001104659-26-064545","cik":"0001374339","ticker":"PMN","issuer_name":"ProMIS Neurosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374339/0001104659-26-064545-index.html","primary_entity_key":"0001374339","primary_entity_name":"ProMIS Neurosciences Inc."},"word_count":381,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security Holders.**\n\nOn May 20, 2026, the Company held its Annual Meeting. The shareholders considered three proposals, each of which is described in more detail in the Company’s Proxy Statement. Of the 8,967,693 Common Shares, no par value per share (the “Common Shares”), outstanding as of the record date, 4,762,024 Common Shares, or approximately 53.1%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.\n\n​\n\n**Proposal No. 1**: Election of seven nominees to serve as directors until the 2027 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The votes were cast as follows by holders of Common Shares:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Name**\n\n**Votes For**\n\n**Votes Withheld**\n\nEugene Williams\n\n​\n\n​\n\n4,108,919\n\n​\n\n38,462\n\n​\n\nNeil Cashman, M.D.\n\n​\n\n​\n\n4,143,889\n\n​\n\n3,492\n\n​\n\nJoshua Mandel-Brehm\n\n​\n\n​\n\n4,118,276\n\n​\n\n29,105\n\n​\n\nMaggie Shafmaster, Ph.D., J.D.\n\n​\n\n​\n\n4,143,725\n\n​\n\n3,656\n\n​\n\nNeil K. Warma\n\n​\n\n​\n\n4,103,311\n\n​\n\n44,070\n\n​\n\nWilliam Wyman\n\n​\n\n​\n\n4,109,684\n\n​\n\n37,697\n\n​\n\nSlanix Alex, Pharm.D\n\n​\n\n​\n\n4,122,179\n\n​\n\n25,202\n\n​\n\n​\n\nBroker non-votes: 614,643.\n\nAll seven nominees were elected.\n\n**Proposal No. 2:** Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows by holders of Common Shares:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Votes For**\n\n**Votes Against**\n\n**Abstained**\n\nRatification of appointment of Baker Tilly US, LLP\n\n4,657,634\n\n​\n\n4,415\n\n​\n\n99,975\n\n​\n\n​\n\nBroker non-votes: 0.\n\n​\n\n**Proposal No. 3**: An ordinary resolution approving the Amendment to the 2025 Stock Option and Incentive Plan to increase the number of Common Shares available for issuance thereunder by 900,000 Common Shares.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Votes For**\n\n**Votes Against**\n\n**Abstained**\n\nApproval of the Amendment to the 2025 Stock Option and Incentive Plan\n\n3,352,388\n\n​\n\n774,193\n\n​\n\n20,800\n\n​\n\n​\n\nBroker non-votes: 614,643.\n\n​\n\nNo other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.\n\n​"}